These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6195513)

  • 41. Differences in conformation of type 3 poliovirus antigenic sites on non-infectious empty particles and infectious virus.
    Ferguson M; Minor PD
    J Gen Virol; 1990 Jun; 71 ( Pt 6)():1271-4. PubMed ID: 1693661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Antigen differences of genetic variants Abent+ and Abent- poliovirus vaccine strain of III type].
    Shyrobokov VP; Kostenko IH; Nikolaienko IV
    Mikrobiol Z; 2003; 65(4):29-36. PubMed ID: 14618784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An evaluation of immune electron microscopy as a method for the quantitation of virus particles.
    Elkana Y; Guttman-Bass N
    J Virol Methods; 1983 Jan; 6(1):53-8. PubMed ID: 6300158
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of virus-neutralizing antibodies by bacteria expressing the C3 poliovirus epitope in the periplasm. The route of immunization influences the isotypic distribution and the biologic activity of the antipoliovirus antibodies.
    LeClerc C; Martineau P; Van der Werf S; Deriaud E; Duplay P; Hofnung M
    J Immunol; 1990 Apr; 144(8):3174-82. PubMed ID: 2157762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antigenic structure of chimeras of type 1 and type 3 poliovirus involving antigenic site 1.
    Minor PD; Ferguson M; Katrak K; Wood D; John A; Howlett J; Dunn G; Burke K; Almond JW
    J Gen Virol; 1990 Nov; 71 ( Pt 11)():2543-51. PubMed ID: 1701474
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Immunoreactivity of chimeric proteins carrying poliovirus epitopes on the VP6 of rotavirus as a vector].
    Pan XX; Zhao BX; Teng YM; Xia WY; Wang J; Li XF; Liao GY; Yang С; Chen YD
    Mol Biol (Mosk); 2016; 50(5):828-837. PubMed ID: 27830685
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antigenicity and immunogenicity of poliovirus capsid proteins.
    van Wezel AL; van der Marel P; Hazendonk TG; Boer-Bak V; Henneke MA
    Dev Biol Stand; 1983; 55():209-15. PubMed ID: 6203795
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A competition immunoprecipitation assay of unlabeled poliovirus antigens.
    Rombaut B; Jore J; Boeyé A
    J Virol Methods; 1994 Jun; 48(1):73-9. PubMed ID: 7962262
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neutralization of poliovirus by polyclonal antibodies requires binding of a single IgG molecule per virion.
    Wetz K; Willingmann P; Zeichhardt H; Habermehl KO
    Arch Virol; 1986; 91(3-4):207-20. PubMed ID: 3022677
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3.
    Evans DM; Minor PD; Schild GS; Almond JW
    Nature; 1983 Aug 4-10; 304(5925):459-62. PubMed ID: 6192344
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A hybridoma cell line secreting antibody to poliovirus type 3 D-antigen: detection in virus harvest of two D-antigen populations.
    Ferguson M; Schild GC; Minor PD; Yates PJ; Spitz M
    J Gen Virol; 1981 Jun; 54(Pt 2):437-42. PubMed ID: 6270261
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hit-and-run neutralization of poliovirus.
    Brioen P; Rombaut B; Boeyé A
    J Gen Virol; 1985 Nov; 66 ( Pt 11)():2495-9. PubMed ID: 2997379
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction of neutralizing antibodies by poliovirus capsid polypeptides VP1, VP2 and VP3.
    van der Marel P; Hazendonk TG; Henneke MA; van Wezel AL
    Vaccine; 1983 Dec; 1(1):17-22. PubMed ID: 6099638
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monospecific antisera against capsid polypeptides of poliovirus type 1 distinguish antigenic structures of poliovirus proteins.
    Wiegers KJ; Dernick R
    J Gen Virol; 1983 Apr; 64 (Pt 4)():777-85. PubMed ID: 6300300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Binding of neutralizing monoclonal antibodies to empty capsids of poliovirus can be blocked by monospecific antisera to structural polypeptides VP1 and VP2.
    Uhlig H; Haardt F; Dernick R
    Arch Virol; 1985; 83(3-4):295-303. PubMed ID: 2578787
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutralization epitope patterns of poliovirus strains isolated from paralytic cases.
    Crainic R; Blondel B; Aubert-Combiescu A; Beytout D; Couillin P; Candrea A; Boué A; Horaud F
    Dev Biol Stand; 1984; 57():165-70. PubMed ID: 6084607
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunoglobulin idiotypes: analysis of viral antigen-antibody systems.
    Kennedy RC; Dreesman GR
    Prog Med Virol; 1985; 31():168-82. PubMed ID: 2578680
    [No Abstract]   [Full Text] [Related]  

  • 58. Antigenic variation of poliovirus caused by antibody components with different specificities.
    Urasawa S; Ishizawa F; Urasawa T
    Microbiol Immunol; 1977; 21(6):299-307. PubMed ID: 198635
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Persistence and class-specificity of neutralizing antibody response induced by trypsin-cleaved type 3 poliovirus in mice.
    Roivainen M; Piirainen L; Hovi T
    Vaccine; 1993; 11(7):713-7. PubMed ID: 7688171
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mapping of antigenic domains in poliovirus VP1 involved in structural rearrangements during virus morphogenesis and antigenic alterations of the virion.
    Ketterlinus R; Wiegers K
    Virology; 1994 Oct; 204(1):27-37. PubMed ID: 7522372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.